Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Decreased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 6.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 380,423 shares of the biopharmaceutical company’s stock after selling 24,233 shares during the quarter. Intra-Cellular Therapies makes up about 3.8% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s investment portfolio, making the stock its 7th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.36% of Intra-Cellular Therapies worth $31,773,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Accredited Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $28,000. Venturi Wealth Management LLC bought a new position in Intra-Cellular Therapies in the 4th quarter worth about $96,000. Wilmington Savings Fund Society FSB grew its position in Intra-Cellular Therapies by 55.7% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 2,069 shares of the biopharmaceutical company’s stock valued at $173,000 after purchasing an additional 740 shares during the last quarter. Covestor Ltd increased its stake in Intra-Cellular Therapies by 15.9% during the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 288 shares in the last quarter. Finally, Barlow Wealth Partners Inc. bought a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $184,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ITCI has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Thursday, May 15th. They set a “hold” rating for the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus target price of $109.70.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.87 on Tuesday. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The company’s fifty day moving average price is $131.80 and its 200-day moving average price is $114.53. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.